Experimental CAR-T therapy targets Hard-to-Treat solid tumors

NCT ID NCT04627740

Completed Disease control Sponsor: Xinqiao Hospital of Chongqing Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tested a new type of immune cell therapy called anti-ALPP CAR-T cells in 5 patients with advanced solid tumors that have a specific marker (ALPP). The goal was to see if the treatment is safe and can shrink tumors. Patients first received chemotherapy to prepare their bodies, then the modified immune cells were infused. The study is complete, but results are not yet widely reported.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anti-ALPP CAR-T cells (a type of immune cell therapy)
What this could lead to: If it works, this could point toward a new treatment option for certain advanced solid tumors that express ALPP.
What could go wrong: This is a very early, small study with only 5 participants, so results may not apply to larger groups. CAR-T therapy can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS

Contacts and locations

Locations

Department of Oncology, Xinqiao Hospital

Chongqing, Chongqing Municipality, 400037, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.